Screener
Cullinan Therapeutics, Inc. CGEM Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermInvestments.
The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336717
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Property and equipment, net | 263 | 421 |
| Operating lease right-of-use assets | 2,233 | 2,630 |
| Other assets | 297 | 297 |
| Long-term investments | 19,020 | 58,270 |
| Total assets | $363,787 | $448,374 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,725 | $841 |
Item 1. Financial Statements.
FAQ
- What is Cullinan Therapeutics, Inc.'s equity method investments?
- Cullinan Therapeutics, Inc. (CGEM) reported equity method investments of $19.02M in Q2 2026.
- How has Cullinan Therapeutics, Inc.'s equity method investments changed year-over-year?
- Cullinan Therapeutics, Inc.'s equity method investments decreased by 92.2% year-over-year, from $242.3M to $19.02M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about Cullinan Therapeutics, Inc.'s equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude